陳遐林　　羅慧群　　劉建江　　王建芳

[關(guān)鍵詞] 肺腺癌;寡轉(zhuǎn)移;培美曲塞;同步放化療;維持治療;生活質(zhì)量

[中圖分類號(hào)] R734.2? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] B? ? ? ? ? [文章編號(hào)] 1673-9701（2021）21-0065-04

Effect of concurrent chemoradiotherapy combined with maintenance therapy on quality of life of patients with EGFR mutation-negative oligometastatic lung adenocarcinoma

CHEN Xialin? ?LUO Huiqun? ?LIU Jianjiang? ?WANG Jianfang

Department of Oncology，Shaoxing People′s Hospital in Zhejiang Province，Shaoxing? 312000，China

[Abstract] Objective To investigate the effect of pemetrexed concurrent chemoradiotherapy combined with pemetrexed maintenance chemotherapy on the quality of life of patients with EGFR mutation-negative oligometastatic lung adenocarcinoma. Methods Forty-one patients with oligometastatic lung adenocarcinoma with negative epidermal growth factor receptor （EGFR） gene mutations who were treated in Shaoxing People′s Hospital in Zhejiang province from May 2018 to June 2019 were selected. Patients were given local radiotherapy for chest primary lesions or local radiotherapy for oligometastatic lesions based on status of patients. Pemetrexed combined with cisplatin chemotherapy was used during radiotherapy，and pemetrexed maintenance therapy was used after the end of chemoradiotherapy. The quality of life scales （EORTC QLQ-C30，QLQ-LC13） were used to evaluate patients at one day before concurrent chemoradiotherapy，within three days after the end of concurrent chemoradiotherapy and two months after the end of concurrent chemoradiotherapy. The results were compared and analyzed. Results In terms of function area，the scores of expect for cognitive function，the physical function，role function，emotional function，social function and general health at the end of concurrent chemoradiotherapy were lower than those before treatment（P<0.05），and were improved at two month after the end of concurrent chemoradiotherapy，among which the difference of improvements of the physical function was statistically significant（P<0.05）. In terms of symptom area，the scores of fatigue，nausea，vomiting，pain，and loss of appetite at the end of concurrent chemoradiotherapy were higher than those before treatment（P<0.05） but were restored to the pre-treatment level at two months after the end of concurrent chemoradiotherapy（P>0.05）. The scores of cough， dysphagia at two months after the end of concurrent chemoradiotherapy were lower than those at the end of concurrent chemoradiotherapy， and the socores of hemoptysis， chest pain were lower than those before treatment （P<0.05）. No significant aggravation or alleviation of other indicators in the symptom area were observed （P>0.05）. Conclusion Pemetrexed concurrent chemoradiotherapy combined with pemetrexed maintenance chemotherapy improves the recent quality of life of patients with EGFR mutation-negative oligometastatic lung adenocarcinoma to some extent.